Trikafta for 6 to 11-year old - your questions answered
Join our host CFA CEO Jo Armstrong along with Mother & Father Kelly & Clay Lotz, Professor Adam Jaffe, and CFA President Mitch Messer.
The Pharmaceutical Benefits Advisory Committee (PBAC) have met to discuss the listing of Trikafta on the Pharmaceutical Benefits Scheme (PBS) for 6- to 11-year-olds. Whilst the decision from this meeting will not be made public until the 16th of December, it is important to discuss what the possible outcomes mean.
This is a crucial decision which will impact the many Australian children currently living with cystic fibrosis.
This Consumer Connect session, CFA have invited a panel of incredible people to discuss, the importance of this decision, what outcomes may be announced, and what these decisions will mean to our community.
We are thrilled to welcome Professor Adam Jaffe to the panel, as he brings with him a wealth of knowledge as to what early access means for our CF kids. Adam is a Paediatric Respiratory Consultant who specializes in children who have chest problems such as cough, asthma, chest infections and rare lung diseases.
In addition, we are delighted to welcome Mother and Father to 7-year-old Chase; Kelly, and Clay Lotz to the panel. Kelly & Clay are doing incredible things in our community to help raise funds and awareness for Cystic Fibrosis Australia. Whilst Chase lives with CF, Kelly and Clay are doing all they can to ensure our CF kids have a brighter future.
Finally, we are pleased to welcome CFA President Mitch Messer to the Panel. Mitch was a member of the Pharmaceutical Benefits Advisory Committee for 12 years and was involved in the development of the first consumer input process to PBAC. He is also a past member of the Research Committee of the National Health & Medical Research Council.
Don’t miss this incredibly valuable session.
This is your chance to ask questions and be a part of the discussion.